JP2012532628A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532628A5 JP2012532628A5 JP2012520702A JP2012520702A JP2012532628A5 JP 2012532628 A5 JP2012532628 A5 JP 2012532628A5 JP 2012520702 A JP2012520702 A JP 2012520702A JP 2012520702 A JP2012520702 A JP 2012520702A JP 2012532628 A5 JP2012532628 A5 JP 2012532628A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- antagonist
- expression level
- vegf
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 claims description 450
- 239000005557 antagonist Substances 0.000 claims description 411
- 239000000523 sample Substances 0.000 claims description 361
- 238000000034 method Methods 0.000 claims description 305
- 238000011282 treatment Methods 0.000 claims description 295
- 108090000623 proteins and genes Proteins 0.000 claims description 206
- 239000013074 reference sample Substances 0.000 claims description 203
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 135
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 135
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 97
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 97
- 206010028980 Neoplasm Diseases 0.000 claims description 86
- 201000011510 cancer Diseases 0.000 claims description 86
- 210000004027 cell Anatomy 0.000 claims description 72
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 72
- 230000002062 proliferating effect Effects 0.000 claims description 72
- 229940121695 NRP 1 antagonist Drugs 0.000 claims description 58
- -1 cMet Proteins 0.000 claims description 56
- 238000011319 anticancer therapy Methods 0.000 claims description 55
- 102000009123 Fibrin Human genes 0.000 claims description 50
- 108010073385 Fibrin Proteins 0.000 claims description 50
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 50
- 229950003499 fibrin Drugs 0.000 claims description 50
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 claims description 43
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 43
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 43
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 43
- 102100037421 Regulator of G-protein signaling 5 Human genes 0.000 claims description 43
- 101710140403 Regulator of G-protein signaling 5 Proteins 0.000 claims description 43
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 claims description 43
- 108090000772 Neuropilin-1 Proteins 0.000 claims description 42
- 230000001225 therapeutic effect Effects 0.000 claims description 41
- 102100040681 Platelet-derived growth factor C Human genes 0.000 claims description 40
- 108010017992 platelet-derived growth factor C Proteins 0.000 claims description 40
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims description 34
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims description 34
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims description 34
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 25
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 claims description 25
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 25
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 claims description 25
- 101000947695 Homo sapiens Microfibrillar-associated protein 5 Proteins 0.000 claims description 25
- 102100036203 Microfibrillar-associated protein 5 Human genes 0.000 claims description 25
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 25
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 25
- 101710183446 C-type lectin domain family 4 member E Proteins 0.000 claims description 16
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 16
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 16
- 101000610543 Homo sapiens Prokineticin-2 Proteins 0.000 claims description 16
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims description 16
- 102100040125 Prokineticin-2 Human genes 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 102100028067 EGF-containing fibulin-like extracellular matrix protein 2 Human genes 0.000 claims description 10
- 101001060248 Homo sapiens EGF-containing fibulin-like extracellular matrix protein 2 Proteins 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 229960000397 bevacizumab Drugs 0.000 claims description 9
- 229940124650 anti-cancer therapies Drugs 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 210000004180 plasmocyte Anatomy 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 102000012545 EGF-like domains Human genes 0.000 claims description 2
- 108050002150 EGF-like domains Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 14
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 102100023068 Protein kinase C-binding protein NELL1 Human genes 0.000 claims 3
- 229940126585 therapeutic drug Drugs 0.000 claims 2
- 208000035475 disorder Diseases 0.000 description 69
- 150000001875 compounds Chemical class 0.000 description 53
- 230000004043 responsiveness Effects 0.000 description 47
- 102000004207 Neuropilin-1 Human genes 0.000 description 39
- 108010082093 Placenta Growth Factor Proteins 0.000 description 36
- 102100035194 Placenta growth factor Human genes 0.000 description 36
- 108091033319 polynucleotide Proteins 0.000 description 20
- 102000040430 polynucleotide Human genes 0.000 description 20
- 239000002157 polynucleotide Substances 0.000 description 20
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 18
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 18
- 101150042788 PROK2 gene Proteins 0.000 description 18
- 102000013008 Semaphorin-3A Human genes 0.000 description 18
- 108010090319 Semaphorin-3A Proteins 0.000 description 18
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 18
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 18
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 18
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 9
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 9
- 101150066399 COL4A1 gene Proteins 0.000 description 9
- 102100029761 Cadherin-5 Human genes 0.000 description 9
- 102100021860 Endothelial cell-specific molecule 1 Human genes 0.000 description 9
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 9
- 108010001498 Galectin 1 Proteins 0.000 description 9
- 102000000795 Galectin 1 Human genes 0.000 description 9
- 102100039555 Galectin-7 Human genes 0.000 description 9
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 9
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 9
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 9
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 description 9
- 101000897959 Homo sapiens Endothelial cell-specific molecule 1 Proteins 0.000 description 9
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 9
- 101000608772 Homo sapiens Galectin-7 Proteins 0.000 description 9
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 9
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 9
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 9
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 9
- 102000004890 Interleukin-8 Human genes 0.000 description 9
- 108090001007 Interleukin-8 Proteins 0.000 description 9
- 102100036034 Thrombospondin-1 Human genes 0.000 description 9
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 9
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 9
- 102000013127 Vimentin Human genes 0.000 description 9
- 108010065472 Vimentin Proteins 0.000 description 9
- 210000005048 vimentin Anatomy 0.000 description 9
- 101150097704 HHEX gene Proteins 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 101001082391 Aspergillus oryzae Beta-hexosaminidase Proteins 0.000 description 1
- 101600105505 Mus musculus Vascular endothelial growth factor C (isoform 1) Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22512009P | 2009-07-13 | 2009-07-13 | |
| US61/225,120 | 2009-07-13 | ||
| US35173310P | 2010-06-04 | 2010-06-04 | |
| US61/351,733 | 2010-06-04 | ||
| PCT/US2010/041706 WO2011008696A2 (en) | 2009-07-13 | 2010-07-12 | Diagnostic methods and compositions for treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016255038A Division JP2017099389A (ja) | 2009-07-13 | 2016-12-28 | 癌治療のための診断方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012532628A JP2012532628A (ja) | 2012-12-20 |
| JP2012532628A5 true JP2012532628A5 (OSRAM) | 2013-08-22 |
| JP6095367B2 JP6095367B2 (ja) | 2017-03-15 |
Family
ID=43227992
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520702A Expired - Fee Related JP6095367B2 (ja) | 2009-07-13 | 2010-07-12 | 癌治療のための診断方法および組成物 |
| JP2016255038A Pending JP2017099389A (ja) | 2009-07-13 | 2016-12-28 | 癌治療のための診断方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016255038A Pending JP2017099389A (ja) | 2009-07-13 | 2016-12-28 | 癌治療のための診断方法および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20110076271A1 (OSRAM) |
| EP (1) | EP2454380A2 (OSRAM) |
| JP (2) | JP6095367B2 (OSRAM) |
| KR (1) | KR20120106935A (OSRAM) |
| CN (2) | CN102482715A (OSRAM) |
| AU (1) | AU2010273585B2 (OSRAM) |
| BR (1) | BR112012000735A2 (OSRAM) |
| CA (1) | CA2766403A1 (OSRAM) |
| HK (1) | HK1226108A1 (OSRAM) |
| IL (1) | IL216926A0 (OSRAM) |
| MX (1) | MX2012000620A (OSRAM) |
| SG (2) | SG10201510152RA (OSRAM) |
| WO (1) | WO2011008696A2 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011153224A2 (en) * | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| US9255927B2 (en) | 2011-05-05 | 2016-02-09 | Duke University | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics |
| US20140348818A1 (en) * | 2011-12-29 | 2014-11-27 | Baylor Research Institute | Biomarkers of kawasaki disease |
| MX356802B (es) | 2012-01-13 | 2018-06-13 | Genentech Inc | Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf. |
| SG11201406184XA (en) * | 2012-03-30 | 2014-10-30 | Genentech Inc | Diagnostic methods and compositions for treatment of cancer |
| WO2014001232A1 (en) * | 2012-06-26 | 2014-01-03 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| EP2903692B1 (en) | 2012-10-08 | 2019-12-25 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
| WO2015013432A1 (en) * | 2013-07-23 | 2015-01-29 | Genentech, Inc. | Model of colorectal cancer |
| CN103911451A (zh) * | 2014-04-11 | 2014-07-09 | 蒋晓东 | 筛选抗血管生成靶向药物治疗肺癌目标人群的方法 |
| RS58957B1 (sr) * | 2014-07-18 | 2019-08-30 | Sanofi Sa | Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka |
| AU2015355731B2 (en) * | 2014-12-03 | 2018-07-26 | Aimed Bio Inc. | Antibody binding to neuropilin 1 and use thereof |
| US10801068B2 (en) | 2015-10-16 | 2020-10-13 | The Trustees Of Columbia University In The City Of New York | JAG1 expression predicts therapeutic response in NASH |
| US11154598B2 (en) * | 2016-03-29 | 2021-10-26 | Université de Paris | Compositions comprising secreted extracellular vesicles of cells expressing NFATC4 useful for the treatment of cancer |
| WO2017181079A2 (en) * | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
| WO2017201166A1 (en) | 2016-05-17 | 2017-11-23 | Duke University | Methods of predicting responsiveness of a cancer to a vegf targeting agent and methods of prognosing and treating cancer |
| CA3026238C (en) * | 2016-06-03 | 2023-07-25 | Samsung Life Public Welfare Foundation | Anti-nrp1 antibody screening method |
| CN106282376A (zh) * | 2016-09-27 | 2017-01-04 | 上海交通大学医学院附属第九人民医院 | 一种用于检测bmp9基因表达的反义rna探针 |
| WO2018127599A1 (en) * | 2017-01-09 | 2018-07-12 | Secarna Pharmaceuticals Gmbh & Co Kg | Oligonucleotides inhibiting the expression of nrp1 |
| WO2018160841A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| CN109828111A (zh) * | 2017-11-23 | 2019-05-31 | 复旦大学附属肿瘤医院 | MFAP5在制备筛选α干扰素干预肝癌敏感人群标志物的制剂中的用途 |
| CN109828114A (zh) * | 2017-11-23 | 2019-05-31 | 复旦大学附属肿瘤医院 | MFAP5蛋白作为筛选α干扰素治疗肝癌敏感人群的试剂盒中的方法及应用 |
| CN113260863A (zh) * | 2018-08-17 | 2021-08-13 | 豪夫迈·罗氏有限公司 | 用于心房纤颤的评价中的循环bmp10 (骨形态发生蛋白10) |
| CN110893238A (zh) * | 2018-09-13 | 2020-03-20 | 常州大学 | 抑制血管内皮生长因子活性和表达量的物质在制备抑制淋巴结转移的产品中的应用 |
| CA3115102A1 (en) * | 2018-10-23 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Anti-npr1 antibodies and uses thereof |
| CN112213495B (zh) * | 2020-09-18 | 2022-10-28 | 广州中医药大学第三附属医院(广州中医药大学第三临床医学院、广州中医药大学附属骨伤科医院、广州中医药大学骨伤科研究所) | 一种辅助诊断或诊断股骨头坏死的标志物 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| DK1167384T3 (da) | 1992-10-28 | 2007-04-10 | Genentech Inc | Vaskular endotheliel cellevækstfaktor antagonister |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| AU710696C (en) | 1995-09-08 | 2002-10-24 | Genentech Inc. | VEGF-related protein |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| EP0885198B1 (en) | 1996-03-05 | 2001-12-19 | AstraZeneca AB | 4-anilinoquinazoline derivatives |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| WO1998002437A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| DK1325932T5 (da) | 1997-04-07 | 2005-10-03 | Genentech Inc | Anti-VEGF antistoffer |
| PT1695985E (pt) | 1997-04-07 | 2011-06-06 | Genentech Inc | Métodos para formar anticorpos humanizados por mutagénese aleatória |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| EP0984930B1 (en) | 1997-05-07 | 2005-04-06 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| CA2291709A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| US6294532B1 (en) | 1997-08-22 | 2001-09-25 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| JP2001518470A (ja) | 1997-09-26 | 2001-10-16 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成阻害剤 |
| JP2001522853A (ja) | 1997-11-11 | 2001-11-20 | ファイザー・プロダクツ・インク | 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体 |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK2020408T3 (da) | 1998-05-29 | 2013-09-30 | Sugen Inc | Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US20020081597A1 (en) | 2000-03-31 | 2002-06-27 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| US6998234B2 (en) * | 2000-11-03 | 2006-02-14 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells |
| AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| PT1638941E (pt) | 2003-05-22 | 2010-08-24 | Abbott Lab | Inibidores de quinases de indazole, benzisoxazole e benzisotiazole |
| MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| KR101227817B1 (ko) * | 2004-04-14 | 2013-01-29 | 제넨테크, 인크. | 혈관 발달을 조절하기 위한 ｅｇｆｌ７ 길항제를 포함하는조성물 및 방법 |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| JP2007070633A (ja) | 2005-09-06 | 2007-03-22 | Lg Electronics Inc | 印刷用インキと蛍光体スラリー組成物、これを用いる印刷機及びプラズマディスプレイパネル並びにその製造方法 |
| UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| ITRM20060337A1 (it) * | 2006-06-27 | 2007-12-28 | Biosoot Srl | Gene tem8 (tumor endotelial marker 8) e sue forme di espressione ed usi diagnostici e terapeutici |
| WO2008128233A1 (en) * | 2007-04-15 | 2008-10-23 | University Of Chicago | Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr) |
| EP2222874A2 (en) * | 2007-11-09 | 2010-09-01 | Genentech, Inc. | Methods and compositions for diagnostic use in cancer patients |
| US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
-
2010
- 2010-07-12 WO PCT/US2010/041706 patent/WO2011008696A2/en not_active Ceased
- 2010-07-12 BR BR112012000735A patent/BR112012000735A2/pt not_active IP Right Cessation
- 2010-07-12 SG SG10201510152RA patent/SG10201510152RA/en unknown
- 2010-07-12 US US12/834,523 patent/US20110076271A1/en not_active Abandoned
- 2010-07-12 JP JP2012520702A patent/JP6095367B2/ja not_active Expired - Fee Related
- 2010-07-12 EP EP10731915A patent/EP2454380A2/en not_active Withdrawn
- 2010-07-12 AU AU2010273585A patent/AU2010273585B2/en not_active Ceased
- 2010-07-12 CN CN2010800365602A patent/CN102482715A/zh active Pending
- 2010-07-12 SG SG2012002432A patent/SG177640A1/en unknown
- 2010-07-12 CA CA2766403A patent/CA2766403A1/en not_active Abandoned
- 2010-07-12 KR KR1020127003607A patent/KR20120106935A/ko not_active Ceased
- 2010-07-12 CN CN201610767315.8A patent/CN106148547A/zh active Pending
- 2010-07-12 MX MX2012000620A patent/MX2012000620A/es unknown
-
2011
- 2011-12-13 IL IL216926A patent/IL216926A0/en unknown
-
2012
- 2012-08-18 HK HK16114547.1A patent/HK1226108A1/zh unknown
-
2013
- 2013-07-10 US US13/938,535 patent/US20140302056A2/en not_active Abandoned
-
2016
- 2016-12-28 JP JP2016255038A patent/JP2017099389A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532628A5 (OSRAM) | ||
| Nienhüser et al. | Angiogenesis and anti-angiogenic therapy in gastric cancer | |
| Baldewijns et al. | VHL and HIF signalling in renal cell carcinogenesis | |
| Dolinay et al. | Inflammasome-regulated cytokines are critical mediators of acute lung injury | |
| Verzola et al. | Toll‐like receptor 4 signalling mediates inflammation in skeletal muscle of patients with chronic kidney disease | |
| Utispan et al. | Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker | |
| Rebouissou et al. | The β-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules | |
| Ma et al. | Negative pressure wound therapy promotes vessel destabilization and maturation at various stages of wound healing and thus influences wound prognosis | |
| US20130316337A1 (en) | Methods of Diagnosing and Treating an Inflammatory Response | |
| KR102739356B1 (ko) | 비알콜성 지방 간 질환, 비알콜성 지방간염 및/또는 간 섬유화의 비침습성 진단 | |
| Kiuchi et al. | Increased vascular endothelial growth factor expression in patients with bladder pain syndrome/interstitial cystitis: its association with pain severity and glomerulations | |
| JP2015512612A5 (OSRAM) | ||
| Sakoda et al. | Enamel matrix derivative induces production of vascular endothelial cell growth factor in human gingival fibroblasts | |
| JP7321931B2 (ja) | 細胞外ベシクル（ｅｖ）の組成物およびその医学的使用 | |
| JP6755241B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP2012522508A5 (OSRAM) | ||
| Wang et al. | MiR-21 regulates epithelial–mesenchymal transition in intestinal fibrosis of Crohn's disease by targeting PTEN/mTOR | |
| JP6612232B2 (ja) | 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用 | |
| Mukwaya et al. | Factors regulating capillary remodeling in a reversible model of inflammatory corneal angiogenesis | |
| Alshanwani et al. | MicroRNA‐21 drives the switch to a synthetic phenotype in human saphenous vein smooth muscle cells | |
| Di Lullo et al. | New evidence of direct oral anticoagulation therapy on cardiac valve calcifications, renal preservation and inflammatory modulation | |
| Aozasa et al. | Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis | |
| ZHenG et al. | Evaluation of glioma-associated oncogene 1 expression and its correlation with the expression of sonic hedgehog, E-cadherin and S100a4 in human hepatocellular carcinoma | |
| Liu et al. | Inhibition of cIAP1/2 reduces RIPK1 phosphorylation in pulmonary endothelial cells and alleviate sepsis-induced lung injury and inflammatory response | |
| Ren et al. | Up‐regulation of macrophage migration inhibitory factor in infants with acute neonatal necrotizing enterocolitis |